VFA
PGNX

Virtus Fund Advisers’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

Virtus Fund Advisers’s Portfolio PGNX Stock Details PGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-5,935
Closed -$26K – 2225
2014
Q2 		$26K Buy
+5,935
New +$22.7K ﹤0.01% 2291

Other funds holding PGNX

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HCMT
Highland Capital Management (Texas) Dallas, Texas $39M AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Virtus Fund Advisers's PGNX Position: Q3 2014 in Review

Virtus Fund Advisers sold out of Progenics Pharmaceuticals Inc (PGNX) in Q3 2014, closing a stake of 5,935 shares — an estimated $26K sold.

Virtus Fund Advisers first reported a position in PGNX in Q2 2014 and held it in 1 quarter. The position peaked at $26K in Q2 2014. 78 funds tracked by Wall St. Rank hold PGNX as of Q3 2014.

  • Virtus Fund Advisers reported no remaining Progenics Pharmaceuticals Inc position as of Q3 2014 after selling out during the quarter.
  • Virtus Fund Advisers sold 5,935 Progenics Pharmaceuticals Inc shares in Q3 2014, an estimated $26K.
  • Virtus Fund Advisers first reported a position in Progenics Pharmaceuticals Inc in Q2 2014 and held it in 1 quarter.
  • Virtus Fund Advisers's Progenics Pharmaceuticals Inc position peaked at $26K in Q2 2014.
  • 78 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q3 2014.

Based on Virtus Fund Advisers's 13F filing for Q3 2014, filed 31 Oct 2014.